Autoimmunity in the pathogenesis and treatment of keratoconjunctivitis sicca

Current Allergy and Asthma Reports

Volumn 14, Issue 1, 2014, Pages

  Liu, Katy C ^a   Huynh, Kyle ^a,b   Grubbs, Joseph ^a   Davis, Richard M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Autoimmunity; Dry eye; Humoral immunity; Immune regulation; Keratoconjunctivitis sicca; Pathogenesis; Sj gren's disease; Treatment

Indexed keywords

AUTOANTIBODY; CEVIMELINE; CYCLOSPORIN A; RITUXIMAB; CYCLOSPORIN; QUINUCLIDINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CELLULAR IMMUNITY; DISEASE ASSOCIATION; DRUG TARGETING; DRY EYE; GENE THERAPY; GENETIC SUSCEPTIBILITY; HELPER CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOREGULATION; KERATOCONJUNCTIVITIS SICCA; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR MIMICRY; PATHOGENESIS; PATHOPHYSIOLOGY; REGULATORY T LYMPHOCYTE; SJOEGREN SYNDROME; TRANSLATIONAL RESEARCH; ANIMAL; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY;

ANIMALS; ANTIGEN-PRESENTING CELLS; APOPTOSIS; AUTOANTIBODIES; AUTOIMMUNITY; CYCLOSPORINE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; KERATOCONJUNCTIVITIS SICCA; MOLECULAR MIMICRY; QUINUCLIDINES; SJOGREN'S SYNDROME; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; THIOPHENES;

EID: 84891512910     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-013-0403-7     Document Type: Article

References (71)

1. Schein OD, Hochberg MC, Munoz B, Tielsch JM, Bandeen-Roche K, Provost T, et al. Dry eye and dry mouth in the elderly: a population-based assessment. Arch Intern Med. 1999;159(12):1359-63.
2. Report of the definition and classification subcommittee of the international dry eye workshop the definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). The Ocular Surface. 2007;5(2):75-92.
3. Gottenberg JE, Busson M, Loiseau P, Cohen-Solal J, Lepage V, Charron D, et al. In primary Sjogren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum. 2003;48(8):2240-5.
4. Chen KS, Jiang MC, Li CJ, Liu OK, Tsai CS. Discrimination between Sjogren's and non-Sjogren's sicca syndrome by sialoscintigraphy and antibodies against alpha-fodrin and Ro/La autoantigens. J Intern Med Res. 2009;37(4):1088-96.
5. Mimori T. Autoantibodies in connective tissue diseases: clinical significance and analysis of target autoantigens. Intern Med. 1999;38(7):523-32.
6. Muller S, Briand JP, Barakat S, Lagueux J, Poirier GG, De Murcia G, et al. Autoantibodies reacting with poly(ADP-ribose) and with a zinc-finger functional domain of poly(ADP-ribose) polymerase involved in the recognition of damaged DNA. Clin Immunol Immunopathol. 1994;73(2):187-96.
7. Haaheim LR, Halse AK, Kvakestad R, Stern B, Normann O, Jonsson R. Serum antibodies from patients with primary Sjogren's syndrome and systemic lupus erythematosus recognize multiple epitopes on the La(SS-B) autoantigen resembling viral protein sequences. Scand J Immunol. 1996;43(1):115-21.
8. Stathopoulou EA, Routsias JG, Stea EA, Moutsopoulos HM, Tzioufas AG. Cross-reaction between antibodies to the major epitope of Ro60 kD autoantigen and a homologous peptide of Coxsackie virus 2B protein. Clin Exp Immunol. 2005;141(1):148-54.
9. Manganelli P, Fietta P. Apoptosis and Sjogren syndrome. Semin Arthritis Rheum. 2003;33(1):49-65.
10. Franz S, Gaipl US, Munoz LE, Sheriff A, Beer A, Kalden JR, et al. Apoptosis and autoimmunity: when apoptotic cells break their silence. Curr Rheumatol Rep. 2006;8(4):245-7.
11. Matsumura R, Umemiya K, Kagami M, Tomioka H, Tanabe E, Sugiyama T, et al. Glandular and extraglandular expression of the Fas-Fas ligand and apoptosis in patients with Sjogren's syndrome. Clin Exp Rheumatol. 1998;16(5):561-8.
12. Polihronis M, Tapinos NI, Theocharis SE, Economou A, Kittas C, Moutsopoulos HM. Modes of epithelial cell death and repair in Sjogren's syndrome (SS). Clin Exp Immunol. 1998;114(3):485-90.
13. Yeh S, Song XJ, Farley W, Li DQ, Stern ME, Pflugfelder SC. Apoptosis of ocular surface cells in experimentally induced dry eye. Investig Ophthalmol Vis Sci. 2003;44(1):124-9.
14. Rosen A, Casciola-Rosen L. Altered autoantigen structure in Sjogren's syndrome: implications for the pathogenesis of autoimmune tissue damage. Crit Rev Oral Biol Med Off Publ Am Assoc Oral Biol. 2004;15(3):156-64.
15. Theofilopoulos AN, Kono DH, Beutler B, Baccala R. Intracellular nucleic acid sensors and autoimmunity. J Interf Cytokine Res Off J Intern Soc Interf Cytokine Res. 2011;31(12):867-86.
16. Yamazaki S, Muta T, Takeshige K. A novel IkappaB protein, IkappaB-zeta, induced by proinflammatory stimuli, negatively regulates nuclear factor-kappaB in the nuclei. J Biol Chem. 2001;276(29):27657-62.
17. Okuma A, Hoshino K, Ohba T, Fukushi S, Aiba S, Akira S, et al. Enhanced apoptosis by disruption of the STAT3-IkappaB-zeta signaling pathway in epithelial cells induces Sjogren's syndrome-like autoimmune disease. Immunity. 2013;38(3):450-60. This recent study finds Sjögren's-like disease develops with disruption of the STAT3-IκB apoptotic pathway.
18. Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem. 2007;282(13):9358-63.
19. Zhang X, Chen W, De Paiva CS, Corrales RM, Volpe EA, McClellan AJ, et al. Interferon-gamma exacerbates dry eye-induced apoptosis in conjunctiva through dual apoptotic pathways. Investig Ophthalmol Vis Sci. 2011;52(9):6279-85.
20. Brignole F, Pisella PJ, Goldschild M, De Saint JM, Goguel A, Baudouin C. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Investig Ophthalmol Vis Sci. 2000;41(6):1356-63.
21. Stern ME, Schaumburg CS, Siemasko KF, Gao J, Wheeler LA, Grupe DA, et al. Autoantibodies contribute to the immunopathogenesis of experimental dry eye disease. Investig Ophthalmol Vis Sci. 2012;53(4):2062-75.
22. Liu X, Wang S, Kao AA, Long Q. The effect of topical pranoprofen 0.1 % on the clinical evaluation and conjunctival HLA-DR expression in dry eyes. Cornea. 2012;31(11):1235-9.
23. Baudouin C, Brignole F, Pisella PJ, De Jean MS, Goguel A. Flow cytometric analysis of the inflammatory marker HLA DR in dry eye syndrome: results from 12 months of randomized treatment with topical cyclosporin A. Adv Exp Med Biol. 2002;506(Pt B):761-9.
24. Hamrah P, Liu Y, Zhang Q, Dana MR. The corneal stroma is endowed with a significant number of resident dendritic cells. Investig Ophthalmol Vis Sci. 2003;44(2):581-9.
25. Pisella PJ, Brignole F, Debbasch C, Lozato PA, Creuzot-Garcher C, Bara J, et al. Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca. Ophthalmology. 2000;107(10):1841-9.
26. Barabino S, Chen Y, Chauhan S, Dana R. Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res. 2012;31(3):271-85.
27. Lin H, Li W, Dong N, Chen W, Liu J, Chen L, et al. Changes in corneal epithelial layer inflammatory cells in aqueous tear-deficient dry eye. Investig Ophthalmol Vis Sci. 2010;51(1):122-8.
28. Moutsopoulos HM, Hooks JJ, Chan CC, Dalavanga YA, Skopouli FN, Detrick B. HLA-DR expression by labial minor salivary gland tissues in Sjogren's syndrome. Ann Rheum Dis. 1986;45(8):677-83.
29. Hamrah P, Liu Y, Zhang Q, Dana MR. Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation. Arch Ophthalmol. 2003;121(8):1132-40.
30. Paul P, van den Hoorn T, Jongsma ML, Bakker MJ, Hengeveld R, Janssen L, et al. A Genome-wide multidimensional RNAi screen reveals pathways controlling MHC class II antigen presentation. Cell. 2011;145(2):268-83.
31. Gupta A, Monroy D, Ji Z, Yoshino K, Huang A, Pflugfelder SC. Transforming growth factor beta-1 and beta-2 in human tear fluid. Curr Eye Res. 1996;15(6):605-14.
32. Zheng X, De Paiva CS, Rao K, Li DQ, Farley WJ, Stern M, et al. Evaluation of the transforming growth factor-beta activity in normal and dry eye human tears by CCL-185 cell bioassay. Cornea. 2010;29(9):1048-54.
33. Shen L, Barabino S, Taylor AW, Dana MR. Effect of the ocular microenvironment in regulating corneal dendritic cell maturation. Arch Ophthalmol. 2007;125(7):908-15.
34. De Paiva CS, Volpe EA, Gandhi NB, Zhang X, Zheng X, Pitcher 3rd JD, et al. Disruption of TGF-beta signaling improves ocular surface epithelial disease in experimental autoimmune keratoconjunctivitis sicca. PloS One. 2011;6(12):e29017.
35. Turpie B, Yoshimura T, Gulati A, Rios JD, Dartt DA, Masli S. Sjogren's syndrome-like ocular surface disease in thrombospondin-1 deficient mice. Am J Pathol. 2009;175(3):1136-47.
36. Li H, Dai M, Zhuang Y. A T cell intrinsic role of Id3 in a mouse model for primary Sjogren's syndrome. Immunity. 2004;21(4):551-60.
37. Niederkorn JY, Stern ME, Pflugfelder SC, De Paiva CS, Corrales RM, Gao J, et al. Desiccating stress induces T cell-mediated Sjogren's Syndrome-like lacrimal keratoconjunctivitis. J Immunol. 2006;176(7):3950-7.
38. Salinas GF, Braza F, Brouard S, Tak PP, Baeten D. The role of B lymphocytes in the progression from autoimmunity to autoimmune disease. Clin Immunol. 2013;146(1):34-45.
39. Cornec D, Devauchelle-Pensec V, Tobon GJ, Pers JO, Jousse-Joulin S, Saraux A. B cells in Sjogren's syndrome: from pathophysiology to diagnosis and treatment. J Autoimmun. 2012;39(3):161-7.
40. Robinson CP, Brayer J, Yamachika S, Esch TR, Peck AB, Stewart CA, et al. Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren's syndrome. Proc Natl Acad Sci U S A. 1998;95(13):7538-43.
41. Voulgarelis M, Moutsopoulos HM. Lymphoproliferation in autoimmunity and Sjogren's syndrome. Curr Rheumatol Rep. 2003;5(4):317-23.
42. Salomonsson S, Jonsson MV, Skarstein K, Brokstad KA, Hjelmstrom P, Wahren-Herlenius M, et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum. 2003;48(11):3187-201.
43. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum. 2005;52(5):1534-44.
44. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Investig. 2002;109(1):59-68.
45. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2(7):465-75.
46. De Paiva CS, Chotikavanich S, Pangelinan SB, Pitcher III JD, Fang B, Zheng X, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal immunol. 2009;2(3):243-53.
47. Perez P, Goicovich E, Alliende C, Aguilera S, Leyton C, Molina C, et al. Differential expression of matrix metalloproteinases in labial salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum. 2000;43(12):2807-17.
48. Goicovich E, Molina C, Perez P, Aguilera S, Fernandez J, Olea N, et al. Enhanced degradation of proteins of the basal lamina and stroma by matrix metalloproteinases from the salivary glands of Sjogren's syndrome patients: correlation with reduced structural integrity of acini and ducts. Arthritis Rheum. 2003;48(9):2573-84.
49. Lee SY, Han SJ, Nam SM, Yoon SC, Ahn JM, Kim TI, et al. Analysis of Tear Cytokines and Clinical Correlations in Sjogren Syndrome Dry Eye Patients and Non-Sjogren Syndrome Dry Eye Patients. Am J Ophthalmol. 2013;156:247-253.
50. Nguyen CQ, Yin H, Lee BH, Carcamo WC, Chiorini JA, Peck AB. Pathogenic effect of interleukin-17A in induction of Sjogren's syndrome-like disease using adenovirus-mediated gene transfer. Arthritis Res Ther. 2010;12(6):R220.
51. Holtta V, Klemetti P, Sipponen T, Westerholm-Ormio M, Kociubinski G, Salo H, et al. IL-23/IL-17 immunity as a hallmark of Crohn's disease. Inflamm Bowel Dis. 2008;14(9):1175-84.
52. Williams RO, Paleolog E, Feldmann M. Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases. Curr Opin Pharmacol. 2007;7(4):412-7.
53. Bernard F, Romano A, Granel B (2010) [Regulatory T cells and systemic autoimmune diseases: systemic lupus erythematosus, rheumatoid arthritis, primary Sjogren's syndrome]. La Revue de medecine interne / fondee par la Societe nationale francaise de medecine interne.(2):116-27. Lymphocytes T regulateurs et maladies auto-immunes systemiques: lupus erythemateux systemique, polyarthrite rhumatoide et syndrome de Gougerot-Sjogren primaire.
54. Chauhan SK, El Annan J, Ecoiffier T, Goyal S, Zhang Q, Saban DR, et al. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol. 2009;182(3):1247-52.
55. Katsifis GE, Rekka S, Moutsopoulos NM, Pillemer S, Wahl SM. Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis. Am J Pathol. 2009;175(3):1167-77.
56. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology. 1999;106(4):811-6.
57. Avunduk AM, Avunduk MC, Varnell ED, Kaufman HE. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol. 2003;136(4):593-602.
58. Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54(3):321-38.
59. Tsubota K, Fujita H, Tadano K, Takeuchi T, Murakami T, Saito I, et al. Improvement of lacrimal function by topical application of CyA in murine models of Sjogren's syndrome. Investig Ophthalmol Vis Sci. 2001;42(1):101-10.
60. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107(4):631-9.
61. Samarkos M, Moutsopoulos HM. Recent advances in the management of ocular complications of Sjogren's syndrome. Curr Allergy Asthma Rep. 2005;5(4):327-32.
62. Gao J, Sana R, Calder V, Calonge M, Lee W, Wheeler LA, et al. Mitochondrial permeability transition pore in inflammatory apoptosis of human conjunctival epithelial cells and T cells: effect of cyclosporin a. Investig Ophthalmol Vis Sci. 2013;54(7):4717-33.
63. Fleck M, Zhang HG, Kern ER, Hsu HC, Muller-Ladner U, Mountz JD. Treatment of chronic sialadenitis in a murine model of Sjogren's syndrome by local fasL gene transfer. Arthritis Rheum. 2001;44(4):964-73.
64. Nakamura S, Shibuya M, Saito Y, Nakashima H, Saito F, Higuchi A, et al. Protective effect of D-beta-hydroxybutyrate on corneal epithelia in dry eye conditions through suppression of apoptosis. Investig Ophthalmol Vis Sci. 2003;44(11):4682-8.
65. Ono M, Takamura E, Shinozaki K, Tsumura T, Hamano T, Yagi Y, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjogren's syndrome: a randomized, double-blind clinical study. Am J Ophthalmol. 2004;138(1):6-17.
66. Fife RS, Chase WF, Dore RK, Wiesenhutter CW, Lockhart PB, Tindall E, et al. Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial. Arch Intern Med. 2002;162(11):1293-300.
67. Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 2002;46(3):748-54.
68. Abdulahad WH, Kroese FG, Vissink A, Bootsma H. Immune regulation and B-cell depletion therapy in patients with primary Sjogren's syndrome. J Autoimmun. 2012;39(1-2):103-11.
69. Rocha EM, Di Pasquale G, Riveros PP, Quinn K, Handelman B, Chiorini JA. Transduction, tropism, and biodistribution of AAV vectors in the lacrimal gland. Investig Ophthalmol Vis Sci. 2011;52(13):9567-72. This study establishes that adenoviral-associated vectors can be delivered to murine lacrimal glands, supporting gene therapy as a potential treatment method for KCS.
70. Rocha EM, Cotrim AP, Zheng C, Riveros PP, Baum BJ, Chiorini JA. Recovery of radiation-induced dry eye and corneal damage by pretreatment with adenoviral vector-mediated transfer of erythropoietin to the salivary glands in mice. Hum Gene Ther. 2013;24(4):417-23.
71. Contreras-Ruiz L, Zorzi GK, Hileeto D, Lopez-Garcia A, Calonge M, Seijo B, et al. A nanomedicine to treat ocular surface inflammation: performance on an experimental dry eye murine model. Gene Ther. 2013;20(5):467-77.